Medy-Tox (086900) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Medy-Tox (086900) reported revenue of 247.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025247.3 billion KRW17.0 billion KRW15.7 billion KRW[source]
2024228.6 billion KRW20.3 billion KRW16.1 billion KRW[source]
2023221.1 billion KRW17.3 billion KRW9.7 billion KRW[source]
2022195.1 billion KRW46.7 billion KRW36.6 billion KRW[source]
2021184.9 billion KRW34.5 billion KRW93.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025563.5 billion KRW122.5 billion KRW440.9 billion KRW[source]
2024593.6 billion KRW123.8 billion KRW469.9 billion KRW[source]
2023592.0 billion KRW125.3 billion KRW466.6 billion KRW[source]
2022561.4 billion KRW146.8 billion KRW414.6 billion KRW[source]
2021547.1 billion KRW158.7 billion KRW388.3 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
202561.4 billion KRW-20.6 billion KRW-37.6 billion KRW[source]
202436.6 billion KRW-647 million KRW-24.0 billion KRW[source]
202313.5 billion KRW13.3 billion KRW-13.5 billion KRW[source]
202226.2 billion KRW-36.1 billion KRW-40.4 billion KRW[source]
202120.0 billion KRW-27.8 billion KRW34.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice